濾胞性リンパ腫治療の世界市場レポート 2025年

濾胞性リンパ腫治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.4％で45億7,000万米ドルに成長します。予測期間の成長は、個別化医療へのアプローチ、免疫療法の進歩、革新的治療へのアクセス拡大、QOLの重視、世界の腫瘍学共同研究イニシアティブなどに起因すると考えられます。予測期間の世界の動向には、臨床試験や調査への取り組み、エピジェネティック修飾因子の探索、放射免疫療法の強化、人工知能（AI）の応用、治療法へのアクセスのための世界な連携などが含まれます。

濾胞性リンパ腫治療市場の予想される成長は、濾胞性リンパ腫の有病率の増加によって推進されると予想されます。ここでいう有病率とは、ある時点または特定の期間に濾胞性リンパ腫と診断された特定の集団内の個人の全体数または割合を指します。この増加は、人口の高齢化、遺伝的素因、診断技術の向上、意識向上とスクリーニングなどの要因によるものです。濾胞性リンパ腫治療は、様々な段階でこの疾患に対処し、その有病率の減少に貢献し、疾患の進行を管理する上で重要な役割を果たします。濾胞性リンパ腫の罹患率は増加傾向にあり、米国がん協会の2023年1月の報告書では、低悪性度濾胞性リンパ腫を含む非ホジキンリンパ腫は米国で最も多いがんであり、がん全体の約4％を占めると述べられています。この予測では、成人・小児ともに約80,550人（男性44,880人、女性35,670人）が新たに罹患すると推定されています。したがって、濾胞性リンパ腫の有病率の増加は、濾胞性リンパ腫治療市場の成長の原動力となっています。

高齢化の進展は、今後数年間の濾胞性リンパ腫治療市場拡大の原動力になると予測されています。高齢化とは、社会における高齢者の割合が時間の経過とともに増加する人口動態を指します。濾胞性リンパ腫の治療は、個別化された治療戦略、患者の全体的なQOLの向上、治療強度の管理など、高齢者特有のヘルスケアニーズに応える上で極めて重要です。例えば、米国に本部を置く世界的組織である国連経済社会局（UNDESA）は2022年、65歳以上の高齢者が世界人口に占める割合が2022年の10％から2050年には16％に増加すると予測していると報告しています。さらに、2050年までに65歳以上の人口は、5歳以下の子どもの数の2倍以上になり、12歳以下の子どもの数とほぼ同数になると予測されています。このように、高齢化人口の増加は濾胞性リンパ腫治療市場の重要な促進要因です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界濾胞性リンパ腫治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の濾胞性リンパ腫治療市場：成長率分析
• 世界の濾胞性リンパ腫治療市場の実績：規模と成長, 2019-2024
• 世界の濾胞性リンパ腫治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界濾胞性リンパ腫治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の濾胞性リンパ腫治療市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体
• 標的療法
• 化学療法
• 放射線治療
• 幹細胞移植
• アルキル化剤
• ヌクレオシド類似体
• アントラサイクリン誘導体
• その他の治療法
• 世界の濾胞性リンパ腫治療市場：製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• タブレット
• カプセル
• 注射剤
• その他の製品タイプ
• 世界の濾胞性リンパ腫治療市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の投与経路
• 世界の濾胞性リンパ腫治療市場：最終用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 腫瘍学センター
• 外来診療センター
• 学術調査機関
• その他のエンドユーザー
• 世界の濾胞性リンパ腫治療市場、モノクローナル抗体のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• リツキシマブ
• オビヌツズマブ
• オファツムマブ
• 世界の濾胞性リンパ腫治療市場、標的療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• PI3K阻害剤
• BTK阻害剤
• BCL-2阻害剤
• 世界の濾胞性リンパ腫治療市場化学療法の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• CHOP療法
• ベンダムスチン
• フルダラビン
• 世界の濾胞性リンパ腫治療市場、放射線治療の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 外部放射線治療（EBRT）
• 放射免疫療法
• 世界の濾胞性リンパ腫治療市場幹細胞移植の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 自家幹細胞移植
• 同種幹細胞移植
• 世界の濾胞性リンパ腫治療市場アルキル化剤の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• シクロホスファミド
• イホスファミド

第7章 地域別・国別分析

• 世界の濾胞性リンパ腫治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の濾胞性リンパ腫治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 濾胞性リンパ腫治療市場：競合情勢
• 濾胞性リンパ腫治療市場：企業プロファイル
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson and Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GlaxoSmithKline plc
• Novartis AG
• Merck & Co. Inc.
• EpiZyme Inc.
• Boehringer Ingelheim GmbH
• CTI BioPharma Corp.
• Spectrum Pharmaceuticals Inc.
• Seattle Genetics Inc.
• Applied Molecular Genetics Inc.
• Daiichi Sankyo Company Ltd.
• Pfizer Inc.
• Incyte Corporation
• MorphoSys AG
• Regeneron Pharmaceuticals Inc.
• Eli Lilly and Company

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 濾胞性リンパ腫治療市場2029：新たな機会を提供する国
• 濾胞性リンパ腫治療市場2029：新たな機会を提供するセグメント
• 濾胞性リンパ腫治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Follicular lymphoma treatment involves medical interventions and therapies aimed at managing and combating the progression of follicular lymphoma, a type of non-Hodgkin lymphoma characterized by abnormal cell growth in the lymphatic system. Typically, the medication is administered intravenously, and early-stage follicular lymphoma may be treated with radiation therapy.

The primary types of treatments for follicular lymphoma include monoclonal antibodies, targeted therapy, chemotherapy, radiation therapy, stem cell transplant, alkylating agents, nucleoside analogues, anthracycline derivatives, and others. Monoclonal antibodies are laboratory-produced proteins designed to mimic the immune system's ability to target specific substances in the body. In follicular lymphoma treatment, they are utilized to target specific proteins on the surface of cancer cells, stimulating the immune system's response. Various products for follicular lymphoma treatment, such as tablets, capsules, injectables, and others, are administered through oral, parenteral, and other routes of administration. These treatments are provided in settings such as hospitals, oncology centers, ambulatory care centers, academic research institutes, and other healthcare facilities.

The follicular lymphoma treatment market research report is one of a series of new reports from The Business Research Company that provides follicular lymphoma treatment market statistics, including follicular lymphoma treatment industry global market size, regional shares, competitors with an follicular lymphoma treatment market share, detailed follicular lymphoma treatment market segments, market trends and opportunities, and any further data you may need to thrive in the follicular lymphoma treatment industry. This follicular lymphoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The follicular lymphoma treatment market size has grown strongly in recent years. It will grow from$3.05 billion in 2024 to $3.31 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to increased incidence of follicular lymphoma, advancements in cancer diagnostics, expanding aging population, clinical research and drug development, and collaborations in oncology research

The follicular lymphoma treatment market size is expected to see strong growth in the next few years. It will grow to $4.57 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to personalized medicine approaches, immunotherapy advancements, expanded access to innovative therapies, focus on quality of life, and global oncology collaboration initiatives. Major trends in the forecast period include clinical trials and research initiatives, exploration of epigenetic modifiers, enhancements in radioimmunotherapy, application of artificial intelligence (AI), and global collaboration for access to therapies.

The anticipated growth in the follicular lymphoma treatment market is expected to be propelled by the increasing prevalence of follicular lymphoma. Prevalence in this context refers to the overall number or percentage of individuals within a specific population diagnosed with follicular lymphoma at a given time or over a particular period. This rise can be attributed to factors such as the aging population, genetic predisposition, improved diagnostic techniques, and heightened awareness and screening. Follicular lymphoma treatment plays a crucial role in addressing the disease at various stages, contributing to the reduction of its prevalence and managing disease progression. The incidence of follicular lymphoma is on the rise, as highlighted by the American Cancer Society's January 2023 report, stating that non-Hodgkin lymphoma, including indolent follicular lymphoma, is the most common cancer in the US, accounting for approximately 4% of all cancers. The projection estimates around 80,550 new cases (44,880 in men and 35,670 in women) for both adults and children. Therefore, the increasing prevalence of follicular lymphoma serves as a driving force for the growth of the follicular lymphoma treatment market.

The growing aging population is projected to drive the expansion of the follicular lymphoma treatment market in the coming years. An aging population refers to a demographic trend where the proportion of elderly individuals within a society increases over time. Treatment for follicular lymphoma is crucial in meeting the specific healthcare needs of older adults, including personalized treatment strategies, improving patients' overall quality of life, and managing treatment intensity. For instance, in 2022, the United Nations Department of Economic and Social Affairs (UNDESA), a global organization based in the U.S., reported that the share of the global population aged 65 and older is expected to rise from 10% in 2022 to 16% by 2050. Additionally, by 2050, the number of people aged 65 and older is projected to be more than double the number of children under age 5 and nearly equal to the number of children under age 12 worldwide. Thus, the increasing aging population is a key driver of the follicular lymphoma treatment market.

The follicular lymphoma treatment market is witnessing a significant trend of technological advancements in both diagnosis and treatment, presenting lucrative opportunities. Companies within this market are embracing advanced diagnostic and treatment approaches for follicular lymphoma to maintain their competitive positions. For example, in December 2022, Genentech Inc., a US-based biotechnology company, obtained FDA approval for Lunsumio-a novel bispecific antibody designed to treat relapsed or refractory follicular lymphoma. Lunsumio represents a new class of fixed-duration cancer treatment immunotherapy, providing a readily available and off-the-shelf treatment option without the need for patients to wait. The FDA approval was based on positive results from the Lunsumio Phase II GO29781 study involving individuals with extensively pretreated follicular lymphoma, particularly those at high risk of disease progression or unresponsive to prior treatments.

Major players in the follicular lymphoma treatment market are directing their efforts toward the development of innovative products, such as CAR-T cell therapy (Chimeric Antigen Receptor T-cell therapy). In May 2022, Novartis AG, a Switzerland-based pharmaceutical company, announced FDA approval for 'Kymriah,' the only CAR-T cell therapy approved to treat relapsed or refractory follicular lymphoma in both adult and pediatric settings. Kymriah, administered as a single infusion, offers a treatment option for patients dealing with follicular lymphoma or blood cancer.

In June 2022, Ipsen, a France-based biopharmaceutical company, acquired Epizyme Inc. for $247 million. This strategic acquisition enhances Ipsen's portfolio by incorporating a pipeline of therapeutic products, including commercially available drugs and treatments for follicular lymphoma. Epizyme Inc., a US-based clinical-stage biopharmaceutical and oncology drug developer, contributes to Ipsen's growth with its expertise in developing medicines for follicular lymphoma and other oncological conditions.

Major companies operating in the follicular lymphoma treatment market include AbbVie Inc., Bayer AG, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson and Johnson Services Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co. Inc., EpiZyme Inc., Boehringer Ingelheim GmbH, CTI BioPharma Corp., Spectrum Pharmaceuticals Inc., Seattle Genetics Inc., Applied Molecular Genetics Inc., Daiichi Sankyo Company Ltd., Pfizer Inc., Incyte Corporation, MorphoSys AG, Regeneron Pharmaceuticals Inc., Eli Lilly and Company, Seagen Inc., Takeda Pharmaceutical Company, Nordic Nanovector ASA, ADC Therapeutics SA, MEI Pharma Inc., BeiGene Inc., TG Therapeutics Inc., Amgen Inc., Dr. Reddy's Laboratories Ltd.

North America was the largest region in the follicular lymphoma treatment market in 2024. The regions covered in the follicular lymphoma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the follicular lymphoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The follicular lymphoma treatment market includes revenues earned by entities by providing drugs, medications, diagnostic devices, radiation therapy equipment, surgical instruments, and devices. Therapies that are used in the treatment of follicular lymphoma. The follicular lymphoma treatment market includes surgery, radiation therapy, chemotherapy, hormonal therapy, targeted therapy, and supportive care.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Follicular Lymphoma Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on follicular lymphoma treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for follicular lymphoma treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The follicular lymphoma treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Monoclonal Antibodies; Targeted Therapy; Chemotherapy; Radiation Therapy; Stem Cell Transplant; Alkylating Agents; Nucleoside Analogues; Anthracycline Derivatives; Other Treatments
• 2) By Product Type: Tablets; Capsules; Injectables; Other Product Types
• 3) By Route of Administration: Oral; Parenteral; Other Route of Administration
• 4) By End Use: Hospitals; Oncology Centers; Ambulatory Care Centers; Academic Research Institutes; Other End Users
• Subsegments:
• 1) By Monoclonal Antibodies: Rituximab; Obinutuzumab; Ofatumumab
• 2) By Targeted Therapy: PI3K Inhibitors; BTK Inhibitors; BCL-2 Inhibitors
• 3) By Chemotherapy: CHOP Regimen; Bendamustine; Fludarabine
• 4) By Radiation Therapy: External Beam Radiation Therapy (EBRT); Radioimmunotherapy
• 5) By Stem Cell Transplant: Autologous Stem Cell Transplant; Allogeneic Stem Cell Transplant
• 6) By Alkylating Agents: Cyclophosphamide; Ifosfamide
• Companies Mentioned: AbbVie Inc.; Bayer AG; Bristol Myers Squibb Company; F. Hoffmann-La Roche Ltd.; Johnson and Johnson Services Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Follicular Lymphoma Treatment Market Characteristics

3. Follicular Lymphoma Treatment Market Trends And Strategies

4. Follicular Lymphoma Treatment Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Follicular Lymphoma Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Follicular Lymphoma Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Follicular Lymphoma Treatment Market Growth Rate Analysis
• 5.4. Global Follicular Lymphoma Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Follicular Lymphoma Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Follicular Lymphoma Treatment Total Addressable Market (TAM)

6. Follicular Lymphoma Treatment Market Segmentation

• 6.1. Global Follicular Lymphoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Targeted Therapy
• Chemotherapy
• Radiation Therapy
• Stem Cell Transplant
• Alkylating Agents
• Nucleoside Analogues
• Anthracycline Derivatives
• Other Treatments
• 6.2. Global Follicular Lymphoma Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablets
• Capsules
• Injectables
• Other Product Types
• 6.3. Global Follicular Lymphoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Route of Administration
• 6.4. Global Follicular Lymphoma Treatment Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Oncology Centers
• Ambulatory Care Centers
• Academic Research Institutes
• Other End Users
• 6.5. Global Follicular Lymphoma Treatment Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rituximab
• Obinutuzumab
• Ofatumumab
• 6.6. Global Follicular Lymphoma Treatment Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• PI3K Inhibitors
• BTK Inhibitors
• BCL-2 Inhibitors
• 6.7. Global Follicular Lymphoma Treatment Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• CHOP Regimen
• Bendamustine
• Fludarabine
• 6.8. Global Follicular Lymphoma Treatment Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• External Beam Radiation Therapy (EBRT)
• Radioimmunotherapy
• 6.9. Global Follicular Lymphoma Treatment Market, Sub-Segmentation Of Stem Cell Transplant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Autologous Stem Cell Transplant
• Allogeneic Stem Cell Transplant
• 6.10. Global Follicular Lymphoma Treatment Market, Sub-Segmentation Of Alkylating Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cyclophosphamide
• Ifosfamide

7. Follicular Lymphoma Treatment Market Regional And Country Analysis

• 7.1. Global Follicular Lymphoma Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Follicular Lymphoma Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Follicular Lymphoma Treatment Market

• 8.1. Asia-Pacific Follicular Lymphoma Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Follicular Lymphoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Follicular Lymphoma Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Follicular Lymphoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Follicular Lymphoma Treatment Market

• 9.1. China Follicular Lymphoma Treatment Market Overview
• 9.2. China Follicular Lymphoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Follicular Lymphoma Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Follicular Lymphoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Follicular Lymphoma Treatment Market

• 10.1. India Follicular Lymphoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Follicular Lymphoma Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Follicular Lymphoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Follicular Lymphoma Treatment Market

• 11.1. Japan Follicular Lymphoma Treatment Market Overview
• 11.2. Japan Follicular Lymphoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Follicular Lymphoma Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Follicular Lymphoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Follicular Lymphoma Treatment Market

• 12.1. Australia Follicular Lymphoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Follicular Lymphoma Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Follicular Lymphoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Follicular Lymphoma Treatment Market

• 13.1. Indonesia Follicular Lymphoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Follicular Lymphoma Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Follicular Lymphoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Follicular Lymphoma Treatment Market

• 14.1. South Korea Follicular Lymphoma Treatment Market Overview
• 14.2. South Korea Follicular Lymphoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Follicular Lymphoma Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Follicular Lymphoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Follicular Lymphoma Treatment Market

• 15.1. Western Europe Follicular Lymphoma Treatment Market Overview
• 15.2. Western Europe Follicular Lymphoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Follicular Lymphoma Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Follicular Lymphoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Follicular Lymphoma Treatment Market

• 16.1. UK Follicular Lymphoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Follicular Lymphoma Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Follicular Lymphoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Follicular Lymphoma Treatment Market

• 17.1. Germany Follicular Lymphoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Follicular Lymphoma Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Follicular Lymphoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Follicular Lymphoma Treatment Market

• 18.1. France Follicular Lymphoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Follicular Lymphoma Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Follicular Lymphoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Follicular Lymphoma Treatment Market

• 19.1. Italy Follicular Lymphoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Follicular Lymphoma Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Follicular Lymphoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Follicular Lymphoma Treatment Market

• 20.1. Spain Follicular Lymphoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Follicular Lymphoma Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Follicular Lymphoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Follicular Lymphoma Treatment Market

• 21.1. Eastern Europe Follicular Lymphoma Treatment Market Overview
• 21.2. Eastern Europe Follicular Lymphoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Follicular Lymphoma Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Follicular Lymphoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Follicular Lymphoma Treatment Market

• 22.1. Russia Follicular Lymphoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Follicular Lymphoma Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Follicular Lymphoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Follicular Lymphoma Treatment Market

• 23.1. North America Follicular Lymphoma Treatment Market Overview
• 23.2. North America Follicular Lymphoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Follicular Lymphoma Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Follicular Lymphoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Follicular Lymphoma Treatment Market

• 24.1. USA Follicular Lymphoma Treatment Market Overview
• 24.2. USA Follicular Lymphoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Follicular Lymphoma Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Follicular Lymphoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Follicular Lymphoma Treatment Market

• 25.1. Canada Follicular Lymphoma Treatment Market Overview
• 25.2. Canada Follicular Lymphoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Follicular Lymphoma Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Follicular Lymphoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Follicular Lymphoma Treatment Market

• 26.1. South America Follicular Lymphoma Treatment Market Overview
• 26.2. South America Follicular Lymphoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Follicular Lymphoma Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Follicular Lymphoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Follicular Lymphoma Treatment Market

• 27.1. Brazil Follicular Lymphoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Follicular Lymphoma Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Follicular Lymphoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Follicular Lymphoma Treatment Market

• 28.1. Middle East Follicular Lymphoma Treatment Market Overview
• 28.2. Middle East Follicular Lymphoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Follicular Lymphoma Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Follicular Lymphoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Follicular Lymphoma Treatment Market

• 29.1. Africa Follicular Lymphoma Treatment Market Overview
• 29.2. Africa Follicular Lymphoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Follicular Lymphoma Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Follicular Lymphoma Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Follicular Lymphoma Treatment Market Competitive Landscape And Company Profiles

• 30.1. Follicular Lymphoma Treatment Market Competitive Landscape
• 30.2. Follicular Lymphoma Treatment Market Company Profiles
  • 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Johnson and Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Follicular Lymphoma Treatment Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline plc
• 31.2. Novartis AG
• 31.3. Merck & Co. Inc.
• 31.4. EpiZyme Inc.
• 31.5. Boehringer Ingelheim GmbH
• 31.6. CTI BioPharma Corp.
• 31.7. Spectrum Pharmaceuticals Inc.
• 31.8. Seattle Genetics Inc.
• 31.9. Applied Molecular Genetics Inc.
• 31.10. Daiichi Sankyo Company Ltd.
• 31.11. Pfizer Inc.
• 31.12. Incyte Corporation
• 31.13. MorphoSys AG
• 31.14. Regeneron Pharmaceuticals Inc.
• 31.15. Eli Lilly and Company

32. Global Follicular Lymphoma Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Follicular Lymphoma Treatment Market

34. Recent Developments In The Follicular Lymphoma Treatment Market

35. Follicular Lymphoma Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Follicular Lymphoma Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Follicular Lymphoma Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Follicular Lymphoma Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer